Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$260.23 USD

260.23
1,560,182

+5.76 (2.26%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $260.28 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

Zacks Equity Research

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.

Zacks Equity Research

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

by Zacks Equity Research

JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.

Zacks Equity Research

Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zacks Equity Research

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Zacks Equity Research

Jazz (JAZZ) International Revenue Performance Explored

by Zacks Equity Research

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Equity Research

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Zacks Equity Research

Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.